Table Graph
      published meta-analysis   sensitivity analysis   studies

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) in COVID-19 prophylaxis (children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultskidCOVE (part 2), 2022 0.26 [0.16; 0.42] teenCOVE (P203) (Adolescents 12-17Y), 2021 0.07 [0.01; 0.46] 0.19[0.07; 0.56]kidCOVE (part 2), 2022, teenCOVE (P203) (Adolescents 12-17Y), 2021241%7,238NAnot evaluable symptomatic Covid-19detailed resultskidCOVE (part 2), 2022 0.12 [0.04; 0.32] 0.12[0.04; 0.32]kidCOVE (part 2), 202210%4,002NAnot evaluable asymptomatic COVID casedetailed resultskidCOVE (part 2), 2022 0.38 [0.20; 0.69] 0.38[0.20; 0.69]kidCOVE (part 2), 202210%4,002NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-05 01:59 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 330 - treatments: 755 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons